Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology

Journal of Clinical Investigation

Volumn 117, Issue 6, 2007, Pages 1595-1604

  Shaftel, Solomon S ^a   Kyrkanides, Stephanos ^a   Olschowka, John A ^a   Miller, Jen Nie H ^a   Johnson, Renee E ^a   O'Banion, M Kerry ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; INTERLEUKIN 1BETA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; GENE ACTIVATION; HIPPOCAMPUS; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SENILE PLAQUE; TRANSGENE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENE EXPRESSION; HIPPOCAMPUS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; PRESENILIN-1; RECOMBINANT PROTEINS; SENILE PLAQUES;

EID: 34249899174     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31450     Document Type: Article

References (45)

1. Basu, A., Krady, J.K., and Levison, S.W. 2004. Interleukin-1: a master regulator of neuroinflammation. J. Neurosci. Res. 78:151-156.
2. Allan, S.M., Tyrrell, P.J., and Rothwell, N.J. 2005. Interleukin-1 and neuronal injury. Nat. Rev. Immunol. 5:629-640.
3. Emsley, H.C., et al. 2005. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatr. 76:1366-1372.
4. Griffin, W.S., et al. 1989. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 86:7611-7615.
5. Van Everbroeck, B., et al. 2002. The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol. Aging. 23:59-64.
6. McGuinness, M.C., et al. 1997. Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. J. Neuroimmunol. 75:174-182.
7. Mrak, R.E., and Griffin, W.S. 1997. The role of chronic self-propagating glial responses in neurodegeneration: implications for long-lived survivors of human immunodeficiency virus. J. Neurovirol. 3:241-246.
8. McGeer, P.L., Itagaki, S., Tago, H., and McGeer, E.G. 1987. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79:195-200.
9. Srinivas, S., et al. 2001. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1:4.
10. Brooks, A.I., Muhkerjee, B., Panahian, N., Cory-Slechta, D., and Federoff, H.J. 1997. Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of cre recombinase. Nat. Biotechnol. 15:57-62.
11. Wingren, A.G., et al. 1996. Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release. Cell. Immunol. 169:226-237.
12. Kyrkanides, S., Miller, J.H., Bowers, W.J., and Federoff, H.J. 2003. Transcriptional and posttranslational regulation of Cre recombinase by RU486 as the basis for an enhanced inducible expression system. Mol. Ther. 8:790-795.
13. Glaccum, M.B., et al. 1997. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J. Immunol. 159:3364-3371.
14. Jankowsky, J.L., et al. 2001. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17:157-165.
15. Jankowsky, J.L., et al. 2004. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13:159-170.
16. Garcia-Alloza, M., et al. 2006. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24:516-524.
17. Griffin, W.S., Liu, L., Li, Y., Mrak, R.E., and Barger, S.W. 2006. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J. Neuroinflammation. 3:5.
18. Simard, A.R., and Rivest, S. 2006. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol. Psychiatry. 11:327-335.
19. Rogers, J., and Lue, L.F. 2001. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 39:333-340.
20. Rogers, J., Strohmeyer, R., Kovelowski, C.J., and Li, R. 2002. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia. 40:260-269.
21. Rogers, J., Luber-Narod, J., Styren, S.D., and Civin, W.H. 1988. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol. Aging. 9:339-349.
22. McGeer, P.L., and McGeer, E.G. 2007. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 28:639-647.
23. Moore, A.H., and O'Banion, M.K. 2002. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv. Drug Deliv. Rev. 54:1627-1656.
24. Griffin, W.S. 2006. Inflammation and neurodegenerative diseases. Am. J. Clin. Nutr. 83:470S-474S.
25. Griffin, W.S., Sheng, J.G., Roberts, G.W., and Mrak, R.E. 1995. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:276-281.
26. Nicoll, J.A., et al. 2000. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann. Neurol. 47:365-368.
27. Bertram, L., McQueen, M.B., Mullin, K., Blacker, D., and Tanzi, R.E. 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39:17-23.
28. Rogers, J.T., et al. 1999. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J. Biol. Chem. 274:6421-6431.
29. Benzing, W.C., et al. 1999. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging. 20:581-589.
30. Lim, G.P., et al. 2000. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20:5709-5714.
31. Simard, A.R., Soulet, D., Gowing, G., Julien, J.P., and Rivest, S. 2006. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 49:489-502.
32. Herber, D.L., et al. 2004. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp. Neurol. 190:245-253.
33. DiCarlo, G., Wilcock, D., Henderson, D., Gordon, M., and Morgan, D. 2001. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol. Aging. 22:1007-1012.
34. Griffin, W.S., et al. 1998. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 8:65-72.
35. Goldgaber, D., et al. 1989. Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 86:7606-7610.
36. Wyss-Coray, T., et al. 2001. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7:612-618.
37. Seabrook, T.J., Jiang, L., Maier, M., and Lemere, C.A. 2006. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia. 53:776-782.
38. D'Andrea, M.R., Cole, G.M., and Ard, M.D. 2004. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging. 25:675-683.
39. Lemere, C.A., Maier, M., Jiang, L., Peng, Y., and Seabrook, T.J. 2006. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 9:77-84.
40. Mentlein, R., Ludwig, R., and Martensen, I. 1998. Proteolytic degradation of Alzheimer's disease amyloid beta-peptide by a metalloproteinase from microglia cells. J. Neurochem. 70:721-726.
41. Malm, T.M., et al. 2005. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis. 18:134-142.
42. Bjorkdahl, O., Akerblad, P., Gjorloff-Wingren, A., Leanderson, T., and Dohlsten, M. 1999. Lymphoid hyperplasia in transgenic mice over-expressing a secreted form of the human interleukin-1beta gene product. Immunology. 96:128-137.
43. Lai, Y.C., et al. 2006. Intraarticular induction of interleukin-1beta expression in the adult mouse, with resultant temporomandibular joint pathologic changes, dysfunction, and pain. Arthritis Rheum. 54:1184-1197.
44. Stalder, A.K., et al. 1998. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. Am. J. Pathol. 153:767-783.
45. O'Banion, M.K., Miller, J.C., Chang, J.W., Kaplan, M.D., and Coleman, P.D. 1996. Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J. Neurochem. 66:2532-2540.